Jane Street’s DexCom DXCM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $11.3M | Sell |
180,100
-39,600
| -18% | -$2.76M | ﹤0.01% | 2380 |
|
|
2025
Q4 | $14.6M | Sell |
219,700
-149,600
| -41% | -$9.67M | ﹤0.01% | 1901 |
|
|
2025
Q3 | $24.9M | Buy |
369,300
+105,600
| +40% | +$8.36M | ﹤0.01% | 1448 |
|
|
2025
Q2 | $23M | Sell |
263,700
-2,500
| -0.9% | -$196K | ﹤0.01% | 1317 |
|
|
2025
Q1 | $18.2M | Buy |
266,200
+9,500
| +4% | +$775K | ﹤0.01% | 1390 |
|
|
2024
Q4 | $20M | Sell |
256,700
-314,600
| -55% | -$23.3M | ﹤0.01% | 1255 |
|
|
2024
Q3 | $38.3M | Buy |
571,300
+140,400
| +33% | +$11.5M | 0.01% | 821 |
|
|
2024
Q2 | $48.9M | Buy |
430,900
+114,800
| +36% | +$14.5M | 0.01% | 701 |
|
|
2024
Q1 | $43.8M | Sell |
316,100
-61,500
| -16% | -$7.73M | 0.01% | 701 |
|
|
2023
Q4 | $46.9M | Buy |
377,600
+123,300
| +48% | +$12.6M | 0.01% | 710 |
|
|
2023
Q3 | $23.7M | Buy |
254,300
+89,700
| +54% | +$10.1M | 0.01% | 973 |
|
|
2023
Q2 | $21.2M | Buy |
164,600
+13,300
| +9% | +$1.61M | 0.01% | 1155 |
|
|
2023
Q1 | $17.6M | Sell |
151,300
-288,100
| -66% | -$32.2M | 0.01% | 1095 |
|
|
2022
Q4 | $49.8M | Sell |
439,400
-16,000
| -4% | -$1.76M | 0.02% | 537 |
|
|
2022
Q3 | $36.7M | Sell |
455,400
-66,100
| -13% | -$5.6M | 0.02% | 666 |
|
|
2022
Q2 | $38.9M | Buy |
521,500
+67,900
| +15% | +$6.2M | 0.02% | 670 |
|
|
2022
Q1 | $58M | Sell |
453,600
-162,800
| -26% | -$17.8M | 0.02% | 616 |
|
|
2021
Q4 | $82.7M | Buy |
616,400
+128,000
| +26% | +$18.4M | 0.03% | 435 |
|
|
2021
Q3 | $66.8M | Buy |
488,400
+177,200
| +57% | +$22.3M | 0.02% | 480 |
|
|
2021
Q2 | $33.2M | Buy |
311,200
+197,600
| +174% | +$19M | 0.01% | 755 |
|
|
2021
Q1 | $10.2M | Sell |
113,600
-190,000
| -63% | -$17.8M | 0.01% | 1533 |
|
|
2020
Q4 | $28.1M | Sell |
303,600
-20,400
| -6% | -$1.82M | 0.01% | 681 |
|
|
2020
Q3 | $33.4M | Sell |
324,000
-85,200
| -21% | -$8.9M | 0.02% | 537 |
|
|
2020
Q2 | $41.5M | Buy |
409,200
+330,000
| +417% | +$29.5M | 0.03% | 416 |
|
|
2020
Q1 | $5.33M | Sell |
79,200
-11,600
| -13% | -$722K | 0.01% | 1137 |
|
|
2019
Q4 | $4.96M | Buy |
90,800
+16,800
| +23% | +$797K | 0.01% | 1098 |
|
|
2019
Q3 | $2.76M | Buy |
74,000
+49,200
| +198% | +$1.91M | ﹤0.01% | 1486 |
|
|
2019
Q2 | $929K | Sell |
24,800
-61,600
| -71% | -$1.94M | ﹤0.01% | 2795 |
|
|
2019
Q1 | $2.57M | Buy |
86,400
+78,800
| +1,037% | +$2.77M | ﹤0.01% | 1754 |
|
|
2018
Q4 | $228K | Sell |
7,600
-14,400
| -65% | -$457K | ﹤0.01% | 4360 |
|
|
2018
Q3 | $787K | Buy |
22,000
+11,200
| +104% | +$347K | ﹤0.01% | 3060 |
|
|
2018
Q2 | $256K | Buy |
+10,800
| New | +$229K | ﹤0.01% | 4301 |
|
|
2017
Q4 | – | Sell |
-29,600
| Closed | -$362K | – | 4674 |
|
|
2017
Q3 | $362K | Sell |
29,600
-324,000
| -92% | -$5.73M | ﹤0.01% | 3473 |
|
|
2017
Q2 | $6.47M | Buy |
353,600
+315,600
| +831% | +$5.83M | 0.02% | 640 |
|
|
2017
Q1 | $805K | Buy |
+38,000
| New | +$742K | ﹤0.01% | 2326 |
|
|
2015
Q4 | – | Sell |
-23,600
| Closed | -$507K | – | 4076 |
|
|
2015
Q3 | $507K | Buy |
23,600
+10,800
| +84% | +$241K | ﹤0.01% | 2293 |
|
|
2015
Q2 | $256K | Buy |
+12,800
| New | +$225K | ﹤0.01% | 2997 |
|
Other funds holding DXCM
VCM
VPM
Jane Street's DXCM Position: Q1 2026 in Review
Jane Street increased its DexCom (DXCM) stake by 1,363% in Q1 2026, buying an estimated $48.1M and bringing the position to 741,669 shares worth $46.6M. The position accounts for 0.01% of the portfolio, ranked #1110.
Jane Street first reported a position in DXCM in Q2 2013 and has held it in 44 quarters since. The position peaked at $129M in Q1 2024. 956 funds tracked by Wall St. Rank hold DXCM as of Q1 2026.
- Jane Street held 741,669 shares of DexCom worth $46.6M as of Q1 2026.
- Jane Street bought 690,966 DexCom shares in Q1 2026, an estimated $48.1M.
- DexCom made up 0.01% of Jane Street's portfolio in Q1 2026, its #1110 holding.
- Jane Street first reported a position in DexCom in Q2 2013 and has held it in 44 quarters since.
- Jane Street's DexCom position peaked at $129M in Q1 2024.
- 956 funds tracked by Wall St. Rank held DexCom as of Q1 2026.
Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.